Page 7 - ஆராய்ச்சி நிறுவனம் க்கு மூலக்கூறு நோயியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Industry News: PharmaFluidics announces ultra-sensitive second generation µPAC™ technology for unbiased single-cell proteomics 18 Feb 2021 PharmaFluidics has announced that researchers of Karl Mechtler’s Group at the Research Institute for Molecular Pathology in Vienna have integrated its ultra-sensitive second generation µPAC™ micro-Chip technology as a key enabler in their advanced Single Cell Proteomics workflow. A newly published joint study available on bioRxiv discloses a 10-fold increase in detection sensitivity, achieved using PharmaFluidics’ second generation µPAC™ technology in an optimized workflow, as compared to previous reports. Key results include untargeted and unbiased analysis achieving identification depth of over 2,000 protein groups from as little as 500 picogram of HeLa tryptic digest.

Paul jacobsJohan devenynsKarl mechtler groupResearch institute for molecular pathologyIndustry newsKarl mechtlerResearch instituteMolecular pathologySingle cell proteomicsPharmafluidics announces ultra sensitive second generation µpac technology for unbiased single cell proteomicsOptimized workflowsProtein identificationபால் ஜாகோப்ஸ்ஆராய்ச்சி நிறுவனம் க்கு மூலக்கூறு நோயியல்தொழில் செய்திஆராய்ச்சி நிறுவனம்